

1 **Supplementary Information**

2

3 **Title:** ATP disrupts lipid binding equilibrium to drive retrograde transport critical for bacterial outer membrane  
4 asymmetry

5

6 **Authors:** Wen-Yi Low<sup>a</sup>, Shuhua Thong<sup>a</sup>, Shu-Sin Chng<sup>a,b,\*</sup>

7

8 **Affiliations:**

9 <sup>a</sup> Department of Chemistry, National University of Singapore, Singapore 117543, Singapore.

10 <sup>b</sup> Singapore Center for Environmental Life Sciences Engineering, National University of Singapore (SCELSE-NUS),  
11 Singapore 117456, Singapore.

12 \* To whom correspondence should be addressed. Email: [chmchngs@nus.edu.sg](mailto:chmchngs@nus.edu.sg)

13

14 **This PDF file includes:**

15 Supplementary Materials and Methods

16 Figures S1 to S8

17 SI References

## 18 **Supplementary Materials and Methods**

### 19 **Overexpression and purification of tagless MlaC bound to [<sup>14</sup>C]-labelled lipids**

20 His-MlaC was over-expressed and purified from BL21( $\lambda$ DE3) cells harboring pETM*His-mlaC*, which encodes  
21 MlaC without its signal sequence but with an N-terminal His<sub>6</sub> tag with a thrombin cleavage site (1). A 3-mL culture  
22 was grown from a single colony in LB broth supplemented with 200  $\mu$ g/mL ampicillin (Sigma-Aldrich) and 1.25  $\mu$ Ci/mL  
23 [<sup>14</sup>C]-acetate (PerkinElmer, NEC084A001MC) at 37 °C until OD<sub>600</sub> ~ 0.6. The cell culture was then used to inoculate  
24 into 150 mL LB broth containing 1.25  $\mu$ Ci/mL [<sup>14</sup>C]-acetate and grown at the same temperature until OD<sub>600</sub> ~ 0.6. 1  
25 mM IPTG (Axil Scientific, Singapore) was added and the culture was grown at 37 °C for another 3 h. Cells were  
26 pelleted by centrifugation at 4,700 x *g* for 20 min using swinging buckets and then resuspended in 8 mL buffer (20  
27 mM Tris.HCl pH 8, 300 mM NaCl, 5 mM imidazole). Buffers were supplemented with 1 mM PMSF (Calbiochem), 50  
28  $\mu$ g/mL DNase I (Sigma-Aldrich) and 100  $\mu$ g/mL lysozyme (Calbiochem). Cells were passed twice through a high-  
29 pressure French Press (French Press G-M, Glen Mills) homogenizer at 20,000 psi. Cell debris was removed by  
30 centrifugation at 4,700 x *g* for 10 min at 4 °C. Subsequently, supernatant was subjected to ultra-centrifugation (Model  
31 Optima L-100K, Beckman Coulter) on a SW 41 Ti rotor at 145,000 x *g* for 1 h at 4 °C to separate membrane and  
32 soluble fractions. Soluble fraction was incubated with 2.5 mL His60 Ni Superflow Resin (Takara Bio Inc) and rocked  
33 for 1 h on ice. The mixture was later loaded onto a column and allowed to drain by gravity. The filtrate was passed  
34 through the resin again, drained and the column was washed with 5 x 20 mL of wash buffer (20 mM Tris.HCl pH 8.0,  
35 300 mM NaCl, 20 mM imidazole) and eluted with 8 mL of elution buffer (20 mM Tris.HCl pH 8.0, 150 mM NaCl, 200  
36 mM imidazole). The eluate was subjected to at least five rounds of buffer exchange centrifugation at 4,000 x *g* with  
37 10 mL TBS (20 mM Tris.HCl pH 8.0, 150 mM NaCl) by using an Amicon Ultra 10 kDa cut-off ultra-filtration device  
38 (Merck Millipore). The solution was then concentrated in a new 10 kDa cut-off ultra-filtration device (by centrifugation  
39 at 4,000 x *g* to ~500  $\mu$ L. Tagless MlaC was prepared by cleaving the N-terminal His-tag with the addition of thrombin  
40 (1 U/0.3 mg His-MlaC) and incubated at 22 °C overnight. After overnight digestion, protease activity was stopped by  
41 adding 2 mM protease inhibitor, PMSF. The tagless MlaC was eventually isolated as the filtrate following incubation  
42 and rocking for 1 h on ice with 2.5 mL His60 Ni Superflow Resin (Takara Bio Inc).

43

### 44 **Radioactive lipid extraction and thin layer chromatography**

45 [<sup>14</sup>C]-labelled PLs were obtained by extracting lipids from membrane fractions that have been metabolically  
46 labelled with [<sup>14</sup>C]-acetate similar to how His-MlaC was over-expressed. 1 mg/100  $\mu$ L of [<sup>14</sup>C]-labelled holo MlaC

47 protein or 1 mL of radiolabeled membrane fraction were used for the PL extraction according to the Bligh-Dyer  
48 method (2). Purified MlaC or the radiolabeled membrane fraction were mixed with 3.75 volumes of  
49 chloroform:methanol:TBS (1:2:0.8 vol/vol). The mixtures were vortexed and sonicated sequentially for 30 seconds  
50 for three times. The mixtures were centrifuged at 21,000 x g for 5 min, and the supernatant was recovered. 1.25  
51 volumes of chloroform and 1.25 volumes of TBS were added to the supernatants. The mixtures were then centrifuged  
52 at 4000 x g for 5 min to separate organic and aqueous phases. The organic phase was gently removed to another  
53 vial, and the organic solvent was evaporated under N<sub>2</sub> gas. The dried lipids were dissolved in 10  $\mu$ L  
54 chloroform:methanol (4:1 vol/vol) and loaded onto a TLC Silica gel 60 F<sub>254</sub> plate (Merck), if necessary. The plate was  
55 developed by the chloroform:methanol:water (65:25:4) solvent system, left to dry at room temperature, and visualized  
56 by phosphor imaging (STORM, GE healthcare).

57

#### 58 **Overexpression and purification of tagless apo MlaC**

59 The purification of apo MlaC was adapted from published protocols (1). 750 mL cell culture pellet from the  
60 growth of BL21( $\lambda$ DE3) cells harboring pETMHis-*mIaC*, was resuspended in 20 mL of lysis buffer (20 mM Tris.HCl pH  
61 8, 300 mM NaCl and 8 M urea). Resuspended cells were rocked for 1.5 h at room temperature. The cells were lysed  
62 with three rounds of sonication on ice (30% power, 5-s pulse on, 5-s pulse off for 3 min). Cell debris was removed  
63 by centrifugation at 4,700 x g for 10 min at 4 °C. Subsequently, the supernatant was subjected to ultra-centrifugation  
64 (Model Optima L-100K, Beckman Coulter) at 145,000 x g for 1 h at 4 °C to separate membrane and soluble fractions.  
65 The supernatant was incubated with 2.5 mL His60 Ni Superflow Resin (Takara Bio Inc) and rocked for 2 h at room  
66 temperature. The resin mixture was later loaded onto a column and allowed to drain by gravity. The filtrate was  
67 passed through the resin again, drained and the column was washed with 2 x 15 mL of wash buffer 1 (20 mM Tris.HCl  
68 pH 8, 300 mM NaCl, 8 M urea and 1% SDS), 2 x 15 mL of wash buffer 2 (20 mM Tris.HCl pH 8, 300 mM NaCl, 8 M  
69 urea) and eluted with 10 mL of elution buffer (20 mM Tris.HCl pH 8.0, 150 mM NaCl, 8 M urea and 500 mM imidazole).  
70 The eluate was pipetted into Spectra/Por 3, 3.5 kDa MWCO, 18 mm flat width dialysis membranes and dialyzed  
71 against TBS for 2 h and then overnight. Next morning, the solution was transferred to a 10 kDa cut-off ultra-filtration  
72 device (Amicon Ultra, Merck Millipore) and concentrated by centrifugation at 4,000 x g to ~500  $\mu$ L. Tagless MlaC  
73 was prepared by cleaving the N-terminal His-tag with the addition of thrombin (1 U/0.3 mg His-MlaC) and incubated  
74 at 22 °C overnight. After overnight digestion, protease activity was stopped by adding 2 mM protease inhibitor, PMSF.  
75 The tagless MlaC was eventually isolated as the filtrate following incubation and rocking for 1 h on ice with 2.5 mL

76 His60 Ni Superflow Resin (Takara Bio Inc). The filtrate was transferred to a 10 kDa cut-off ultra-filtration device  
77 (Amicon Ultra, Merck Millipore) and concentrated by centrifugation at 4,000 x g to ~500  $\mu$ L. The protein was further  
78 purified by SEC system (AKTA, GE Healthcare) at 4 °C on a prepacked Superdex 200 increase 10/300 GL column  
79 using TBS, as the running buffer.

## 80 81 **Overexpression and purification of membrane protein complexes**

82 The purification of MlaFEDB/MlaFEB complexes was adapted from published protocols (3). MlaF(His-E)DB,  
83 MlaF<sub>K47A</sub>(His-E)DB, MlaF(His-E)<sub>DL106N/L107N</sub>B and MlaF(His-E)<sub>D $\Delta$ 141-183</sub>B were over-expressed and purified from  
84 BL21( $\lambda$ DE3) cells harboring pET22/42*m*laF(His-E)DCB, pET22/42*m*laF<sub>K47A</sub>(His-E)DCB, pET22/42*m*laF(His-  
85 E)<sub>DL106N/L107N</sub>CB and pET22/42*m*laF(His-E)<sub>D $\Delta$ 141-183</sub>CB, respectively. In order to optimize amounts of MlaB during the  
86 complex purification, a second over-expression vector pCDF*m*laB was introduced into BL21( $\lambda$ DE3) cells. To  
87 overexpress MlaF(His-E)DB<sub>T52A</sub>, pCDF*m*laB<sub>T52A</sub> together with pET22/42*m*laF(His-E)DCB<sub>T52A</sub> were introduced into  
88 BL21( $\lambda$ DE3) cells. To over-express MlaF(His-E)B, pCDF*m*laB together with pET22/42*m*laF(His-E) were introduced  
89 into BL21( $\lambda$ DE3) cells. A 30-mL culture was grown from a single colony in LB broth supplemented with 200  $\mu$ g/mL  
90 ampicillin (Sigma-Aldrich) and 50  $\mu$ g/ mL streptomycin (Sigma-Aldrich) at 37 °C until OD<sub>600</sub> ~ 0.6. The cell culture  
91 was then used to inoculate a 3-L culture and grown at the same temperature until OD<sub>600</sub> ~ 0.6. For MlaF(His-E)DB  
92 and associated variant complexes, 1 mM IPTG (Axil Scientific, Singapore) was added and the culture was grown at  
93 37 °C for another 3 h. For MlaF(His-E)B complex, 0.1 mM IPTG was added and the culture was grown at 18 °C for  
94 another 20 h. Cells were pelleted by centrifugation at 4700 x g for 20 min and then resuspended in 25 mL buffer (20  
95 mM Tris.HCl pH 8, 300 mM NaCl) buffer containing 1 mM PMSF (Calbiochem), 50 mg/mL DNase I (Sigma-Aldrich)  
96 and 100 mg/mL lysozyme (Calbiochem). Cells were passed twice through a high pressure French Press (French  
97 Press G-M, Glen Mills) homogenizer at 20,000 psi. Cell debris was removed by centrifugation at 4700 x g for 10 min  
98 at 4 °C. Subsequently, the supernatant was subjected to ultra-centrifugation (Model Optima L-100K, Beckman  
99 Coulter) at 145,000 x g for 1 h at 4 °C to separate membrane and soluble fractions. The membrane pellet fraction  
100 was extracted (20 mL of 20 mM Tris.HCl pH 8.0, 300 mM NaCl, 5 mM MgCl<sub>2</sub>, 10% glycerol, 1% n-dodecyl b-D-  
101 maltoside (DDM) (Merck Millipore), 10 mM imidazole and 1 mM PMSF) and subjected to a second round of ultra-  
102 centrifugation at 145,000 x g for 1 h at 4 °C. The supernatant was incubated with 2.5 mL His60 Ni Superflow Resin  
103 (Takara Bio Inc) and rocked for 2 h on ice. The mixture was later loaded onto a column and allowed to drain by  
104 gravity. The filtrate was passed through the resin again, drained and the column was washed with 10 x 10 mL of

105 wash buffer (20 mM Tris.HCl pH 8.0, 300 mM NaCl, 20 mM imidazole, 1mM PMSF, 5 mM MgCl<sub>2</sub>, 10% glycerol and  
106 0.05% DDM) and eluted with 15 mL of elution buffer (20 mM Tris.HCl pH 8.0, 150 mM NaCl, 200 mM imidazole,  
107 1mM PMSF, 5 mM MgCl<sub>2</sub>, 10% glycerol and 0.05% DDM). The eluate was concentrated in an Amicon Ultra 10 kDa  
108 cut-off ultra-filtration device (Merck Millipore) by centrifugation at 4,000 x *g* to ~500 μL. Proteins were further purified  
109 by size-exclusion chromatography (SEC) system (AKTA, GE Healthcare, UK) at 4 °C on a pre-packed Superdex 200  
110 increase 10/300 GL column, using 20 mM Tris.HCl pH 8.0, 150 mM NaCl, 5 mM MgCl<sub>2</sub>, 10% glycerol and 0.05%  
111 DDM as the eluent. For MlaF(His-E)B complexes, two columns were connected in series to allow better peak  
112 separation.

113

#### 114 **Overexpression and purification of membrane scaffold protein MSP1E3D1-His**

115 The purification of MSP1E3D1-His was adapted from published protocols (4). MSP1E3D1 nanodiscs (~12.9  
116 nm in diameter) were chosen because measured ATPase activities of MlaFEDB complexes (~11 nm in diameter)  
117 reconstituted in MSP1E3D1 or larger MSP2N2 (15.0-16.5 nm in diameter) nanodiscs did not exhibit any distinct  
118 differences, indicating that the size of the MSP1E3D1 nanodisc is sufficient in the context of ATP hydrolysis and PL  
119 transfer. MSP1E3D1-His was over-expressed and purified from BL21(λDE3) cells harboring pMSP1E3D1. A 15-mL  
120 culture was grown from a single colony in LB broth supplemented with 25 μg/mL kanamycin (Sigma-Aldrich) at 37  
121 °C until OD<sub>600</sub> ~ 0.6. The cell culture was then used to inoculate a 1.5-L culture and grown at the same temperature  
122 until OD<sub>600</sub> ~ 0.6. 1 mM IPTG (Axil Scientific, Singapore) was added and the culture was grown at 37 °C for another  
123 3 h. Cells were pelleted by centrifugation at 4700 x *g* for 20 min and then resuspended in 20 mL of 20 mM phosphate  
124 buffer pH 7.4 buffer containing 1 mM PMSF (Calbiochem), 50 mg/mL DNase I (Sigma-Aldrich) and 1% Triton X-100  
125 (Sigma-Aldrich). Cells were passed twice through a high pressure French Press (French Press G-M, Glen Mills)  
126 homogenizer at 20,000 psi. Cell debris was removed by centrifugation at 4700 x *g* for 10 min at 4 °C. Subsequently,  
127 the supernatant was subjected to ultra-centrifugation (Model Optima L-100K, Beckman Coulter) at 145,000 x *g* for 1  
128 h at 4 °C to separate membrane and soluble fractions. Soluble fraction was incubated with 2.5 mL His60 Ni Superflow  
129 Resin (Takara Bio Inc) and rocked for 1 h on ice. The filtrate was passed through the resin again, drained and the  
130 column was washed with 25 mL of wash buffer 1 (40 mM Tris.HCl pH 8.0, 300 mM NaCl and 1% Triton X-100), 25  
131 mL of wash buffer 2 (40 mM Tris.HCl pH 8.0, 300 mM NaCl, 50 mM Na-cholate and 20 mM imidazole), and 25 mL  
132 of wash buffer 3 (40 mM Tris.HCl pH 8.0, 300 mM NaCl and 50 mM imidazole). The proteins were eluted from the  
133 column with 8 mL of elution buffer (40 mM Tris.HCl pH 8.0, 300 mM NaCl and 400 mM imidazole). The eluate was

134 pipetted into Spectra/Por 3, 3.5 kDa MWCO, 18 mm flat width dialysis membranes and dialyzed against buffer (20  
135 mM Tris.HCl pH 7.4, 100 mM NaCl and 0.5 mM EDTA) overnight.

136

### 137 **Enzyme-coupled ATPase assay**

138 ATP hydrolytic activity was determined using an NADH enzyme-linked assay (5) adapted for a microplate  
139 reader (6), as previously described (3). 50  $\mu$ L reactions contained assay buffer (TBS for nanodisc-embedded  
140 samples; 20 mM Tris. HCl pH 8.0, 150 mM NaCl, 5 mM MgCl<sub>2</sub>, 10% glycerol, 0.05% DDM for detergent-solubilized  
141 samples) with 200  $\mu$ M NADH (Sigma- Aldrich), 20 U/mL lactic dehydrogenase (Sigma-Aldrich), 100 U/mL pyruvate  
142 kinase (Sigma-Aldrich), 0.5 mM phosphoenolpyruvate (Alfa Aesar) and different ATP (Sigma-Aldrich) concentrations.  
143 The assay were performed at either 37°C or room temperature and fluorescence emission at 340 nm was measured  
144 using a SPECTRAmax 250 microplate spectrophotometer equipped with SOFTmax PRO software (Molecular  
145 Devices, CA, USA). Readings were taken in ~9 s intervals. The rate of decrease of NADH fluorescence (due to  
146 oxidation) was calculated from a linear fit to each 10 min time course and converted to ATP hydrolysis rates with a  
147 standard curve obtained using known ADP concentrations. Where indicated, holo and apo MlaC were added in a 5:1  
148 ratio to nanodisc-embedded MlaFEDB complex used. Vanadate was also used at concentrations of 0.6, 1.2 and 2.7  
149 mM. Samples were performed in technical triplicates and data were fit to the built-in Hill equation in OriginPro 2018b.

150 Both ATP (Sigma-Aldrich) and AMP-PNP (Sigma-Aldrich) were prepared by adjusting the solution pH to pH  
151 8. Sodium orthovanadate (Sigma-Aldrich) was prepared in water adjusted to pH 10. The solution was boiled until  
152 clear to ensure presence of vanadate monomers. Upon cooling down to room temperature, the pH was re-adjusted  
153 to pH 10. Repeated cycles of boiling and pH adjustment was done until the solution remains clear at pH 10.

154


### 155 **SDS-PAGE, BN-PAGE, immunoblotting and staining**

156 All samples subjected to SDS-PAGE were mixed with equal amounts of 2X Laemmli reducing buffer. Equal  
157 volumes of the unheated samples were loaded onto the gels. Unless otherwise stated, SDS-PAGE was performed  
158 according to Laemmli using the using 4-12% Tris.HCl stacking gels (7). After SDS-PAGE, gels were visualized by  
159 either Coomassie blue staining (InstantBlue™, expedeon), silver staining (Life Technologies) or subjecting to  
160 immunoblotting. BN-PAGE was performed according to published protocols (8) with the usage of 4–20% Tris.HCl  
161 polyacrylamide gel. Immunoblotting was performed by transferring protein bands from the gels onto polyvinylidene  
162 fluoride (PVDF) membranes (Immun-Blot® 0.2  $\mu$ m, Bio-Rad) using semi-dry electroblotting system (Trans-Blot®

163 Turbo™ Transfer System, Bio-Rad). Membranes were blocked by 1X casein blocking buffer (Sigma-Aldrich).  $\alpha$ -His  
164 antibody (pentahistidine) conjugated to the horseradish peroxidase (HRP) (Qiagen) was used at a dilution of 1:5,000.  
165 Rabbit  $\alpha$ -MlaC (1) was used at a dilution of 1:500. Donkey  $\alpha$ -Rabbit conjugated to HRP (GE Healthcare) was used  
166 at a dilution of 1:5000. Luminata Forte Western HRP Substrate (Merck Milipore) was used to develop the membranes  
167 and chemiluminescence signals were visualized by G:Box Chemi-XX 6 (Genesys version 1.4.3.0, Syngene). For gels  
168 ran with radioactive samples, gels were directly dried via the DryEase® Mini-Gel Drying System (Invitrogen)  
169 overnight, after being subjected to either Coomassie blue or silver staining. The dried gels were subsequently imaged  
170 by a scanner (CanoScan LiDE 20, Canon).

171 **Supplementary Figures**

172




173

174 **Figure S1.** Nanodisc-embedded MlaFEDB complex displays high ATP hydrolytic activity at physiological temperature  
 175 (37°C) but is not further activated by MlaC. (A) Enzyme-coupled ATPase assays of nanodisc-embedded or detergent-  
 176 solubilized MlaFEDB complexes (0.1 μM) at either 37°C or room temperature. Average ATP hydrolysis rates from  
 177 triplicate experiments were plotted against ATP concentrations and fitted to an expanded Michaelis-Menten equation  
 178 that includes a term for Hill coefficient ( $n$ ); MlaFEDB (NDs, 37°C) ( $k_{cat} = 0.090 \pm 0.002 \mu\text{mol ATP s}^{-1}/\mu\text{mol complex}$ ,  
 179  $K_m = 82.5 \pm 4.3 \mu\text{M}$ ,  $n = 1.9 \pm 0.2$ ), MlaFEDB (NDs, RT) ( $k_{cat} = 0.029 \pm 0.024 \mu\text{mol ATP s}^{-1}/\mu\text{mol complex}$ ), MlaFEDB  
 180 (DDM, 37°C) ( $k_{cat} = 0.540 \pm 0.079 \mu\text{mol ATP s}^{-1}/\mu\text{mol complex}$ ,  $K_m = 125.8 \pm 40.7 \mu\text{M}$ ,  $n = 1.2 \pm 0.3$ ) and MlaFEDB  
 181 (DDM, RT) ( $k_{cat} = 0.126 \pm 0.008 \mu\text{mol ATP s}^{-1}/\mu\text{mol complex}$ ,  $K_m = 62.8 \pm 7.6 \mu\text{M}$ ,  $n = 1.9 \pm 0.5$ ). (B) Enzyme-coupled  
 182 ATPase assays of nanodisc-embedded MlaFEDB complexes (0.1 μM) at 37°C in the presence of 5-fold excess of




183 apo or holo MlaC. MlaFEDB (NDs) ( $k_{\text{cat}} = 0.220 \pm 0.000 \mu\text{mol ATP s}^{-1}/\mu\text{mol complex}$ ,  $K_m = 75.0 \pm 8.0 \mu\text{M}$ ,  $n = 1.9 \pm$   
184  $0.4$ ), MlaFEDB (NDs with holo MlaC) ( $k_{\text{cat}} = 0.209 \pm 0.008 \mu\text{mol ATP s}^{-1}/\mu\text{mol complex}$ ,  $K_m = 67.2 \pm 4.0 \mu\text{M}$ ,  $n = 1.6$   
185  $\pm 0.2$ ), and MlaFEDB (NDs with apo MlaC) ( $k_{\text{cat}} = 0.332 \pm 0.207 \mu\text{mol ATP s}^{-1}/\mu\text{mol complex}$ ,  $K_m = 156.8 \pm 367.6 \mu\text{M}$ ,  
186  $n = 0.5 \pm 0.4$ ). Errors depicted by bars and  $\pm$  signs are SDs of triplicate data. SDS-PAGE analysis of the complexes  
187 used for these assays is shown on the right. \*, pyruvate kinase/lactate dehydrogenase enzymes used in coupled  
188 assay; <, degraded MSP1E3D1. CB, Coomassie blue staining.



189

190 **Figure S2.** Tagless MlaC is purified bound to [<sup>14</sup>C]-labelled lipids and can be separated cleanly from His-tagged  
 191 nanodisc-embedded MlaFEDB complex. (A) SDS-PAGE analysis of His-tagged and thrombin-digested tagless MlaC  
 192 purified from cells metabolically labelled with [<sup>14</sup>C]-acetate. CB, Coomassie blue staining. (B) Thin-layer  
 193 chromatography (TLC)/phosphor imaging analysis of the organic extracts from thrombin-digested MlaC, revealing

194 presence of bound [<sup>14</sup>C]-labelled lipids, phosphatidylethanolamine (PE) and phosphatidylglycerol (PG). Lipids are  
195 annotated as such because previous work using <sup>31</sup>P NMR analysis indicated that lipids co-purified with MlaC consist  
196 of ~50% PG and ~50% PE, with no detectable <sup>31</sup>P signal from cardiolipin (1). (C) Immunoblot analyses using α-His  
197 or α-MlaC antibodies, showing clean separation of non-radioactive tagless holo MlaC (10 μM) and non-radioactive  
198 His-tagged nanodisc-embedded complexes (2 μM) by nickel affinity resin. !, holo MlaC; #, nanodisc-embedded  
199 MlaFEDB; %, nanodisc-embedded MlaFEB.



200

201

202



203


204

205

206

**Figure S3.** Spontaneous transfer of [ $^{14}\text{C}$ ]-labelled lipids from MlaC to MlaFEDB decreases when an increased concentration of MlaC is used. Average gains of radioactivity ([ $^{14}\text{C}$ ]-lipids) in the indicated nanodiscs from three sets of triplicate experiments, normalized to the initial counts on MlaC when incubated with (A) 2  $\mu\text{M}$  MlaC and (B) 10  $\mu\text{M}$  MlaC. Data from coincubation of MlaFEDB/MlaC are treated as unspecific background transfer/loss and have been subtracted. Student's *t* tests: \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .


**A****B**



209

210 **Figure S4.** Holo MlaC bound with [<sup>14</sup>C]-labelled lipids can be separated from nanodisc-embedded MlaFEDB  
 211 complexes in assays that probe for the effect of ATP hydrolysis on PL transfer. (A) SDS-PAGE analysis of the  
 212 complexes used in the enzyme-coupled ATPase assay shown in Figure 3A. \*, pyruvate kinase/lactate  
 213 dehydrogenase enzymes used in coupled assay; <, degraded MSP1E3D1. CB, Coomassie blue staining. (B-E) SDS-  
 214 PAGE analyses of indicated samples following coincubation and subsequent nickel affinity-based separation of

215 tagless [<sup>14</sup>C]-PL bound (holo) MlaC (10 μM) and His-tagged non-radioactive nanodisc-embedded complexes (2 μM),  
216 for (B) ATPase mutant complexes, (C) addition of AMP-PNP, (D) addition of vanadate (2.7 mM, and (E) different  
217 ATP concentrations as shown in Figure 3B-E. †, [<sup>14</sup>C]-holo MlaC; #, nanodisc-embedded MlaFEDB; &, MlaF<sub>K47A</sub>EDB;  
218 ^, MlaFEDB<sub>T52A</sub>; %, nanodisc-embedded MlaFEB; SS, silver staining.






219


220 **Figure S5.** Vanadate inhibits the ATPase activity of nanodisc-embedded MlaFEDB complex. Enzyme-coupled  
 221 ATPase assays of nanodisc-embedded MlaFEDB (0.1  $\mu\text{M}$ ) in the presence of 0, 0.6, 1.2 and 2.7 mM vanadate at  
 222 37°C. Average ATP hydrolysis rates from triplicate experiments were plotted against ATP concentrations and fitted  
 223 to an expanded Michaelis-Menten equation that includes a term for Hill coefficient ( $n$ ); MlaFEDB NDs (0 mM  
 224 vanadate) ( $k_{\text{cat}} = 0.178 \pm 0.012 \mu\text{mol ATP s}^{-1}/\mu\text{mol complex}$ ,  $K_m = 70.7 \pm 9.0 \mu\text{M}$ ,  $n = 1.8 \pm 0.4$ ), MlaFEDB NDs (0.6  
 225 mM vanadate) ( $k_{\text{cat}} = 0.098 \pm 0.013 \mu\text{mol ATP s}^{-1}/\mu\text{mol complex}$ ,  $K_m = 56.8 \pm 12.3 \mu\text{M}$ ,  $n = 1.4 \pm 0.6$ ), MlaFEDB NDs  
 226 (1.2 mM vanadate) ( $k_{\text{cat}} = 0.051 \pm 0.017 \mu\text{mol ATP s}^{-1}/\mu\text{mol complex}$ ,  $K_m = 24.7 \pm 20.5 \mu\text{M}$ ,  $n = 0.7 \pm 1.1$ ) and  
 227 MlaFEDB NDs (2.7 mM vanadate) ( $k_{\text{cat}} = 0.037 \pm 0.934 \mu\text{mol ATP s}^{-1}/\mu\text{mol complex}$ ). Errors depicted by bars and  $\pm$   
 228 signs are SDs of triplicate data. At 2.7 mM vanadate, the ATPase activity of the complex (0.1  $\mu\text{M}$ ) is likely fully  
 229 inhibited; we believe the 'baseline ATPase activity' observed is due to background NADH oxidation induced by  
 230 vanadate in the enzyme-coupled ATPase assay that we use (9). However, this background is quite low in the context  
 231 of the high ATP hydrolytic activity observed for the MlaFEDB complex, thus minimally affects the interpretation of  
 232 vanadate inhibition experiments.

233






235 **Figure S6.** MlaFED $\Delta$ 141-183B forms hexamers in the complex that are non-SDS-resistant, unlike in wildtype MlaFEDB  
236 and MlaFED<sub>L106N/L107N</sub>B. (A) Size-exclusion chromatographic (SEC) profiles of detergent-solubilized MlaFEDB (*black*)  
237 and MlaFED $\Delta$ 141-183B (*red*) complex. The number beside each peak represents their respective elution volume. The  
238 arrows at the axis represent standards (1) thyroglobulin, (2) ferritin, (3) aldolase and (4) conalbumin at their respective  
239 elution volumes on a Superdex 200 Increase 10/300 GL column. The difference in elution volumes roughly  
240 corresponds to a mass shift of ~25 kDa, consistent with the loss of six C-terminal regions of MlaD, each comprising  
241 43 amino acids (~4.4 kDa). (B) BN-PAGE analysis of SEC-purified MlaFEDB, MlaFED<sub>L106N/L107N</sub>B and MlaFED $\Delta$ 141-  
242 <sub>183</sub>B complex in DDM. The bands indicated were excised and subjected to another SDS-PAGE analysis. (C) SDS-  
243 PAGE analysis of the excised bands from B shows that MlaFED $\Delta$ 141-183B complex does not form SDS-resistant  
244 hexamers unlike that in wildtype and MlaD<sub>L106N/L107N</sub>B. CB, Coomassie blue staining.



**B**




245


246 **Figure S7.** Holo MlaC bound with  $^{14}\text{C}$ -labelled lipids can be separated from nanodisc-embedded MlaFEDB,  
 247 MlaFED<sub>L106N/L107N</sub>B and MlaFED <sub>$\Delta$ 141-183</sub>B complexes in assays that probe for the effects of MlaD on PL transfer. (A)  
 248 SDS-PAGE analysis of indicated samples following coincubation with or without ATP, and subsequent nickel affinity-  
 249 based separation of tagless  $^{14}\text{C}$ -PL bound (holo) MlaC (10  $\mu\text{M}$ ) and His-tagged non-radioactive nanodisc-embedded  
 250 complexes containing MlaD variants (2  $\mu\text{M}$ ) as shown in Figure 4A. !,  $^{14}\text{C}$ -holo MlaC; #, nanodisc-embedded  
 251 MlaFEDB; @, MlaFED<sub>L106N/L107N</sub>B; /, MlaFED <sub>$\Delta$ 141-183</sub>B; %, nanodisc-embedded MlaFEB; SS, silver staining. (B) SDS-

252 PAGE analysis of the complexes used in the enzyme-coupled ATPase assay shown in Figure 4B. \*, pyruvate  
253 kinase/lactate dehydrogenase enzymes used in coupled assay. CB, Coomassie blue staining.

**A**



**B**



254

255 **Figure S8.** MlaFEDB and MlaFEB complexes are reconstituted into nanodiscs containing [<sup>14</sup>C]-labelled PLs and  
256 purified by size exclusion chromatography. SDS-PAGE analyses of samples from indicated collected fractions (0.5  
257 mL each) of reconstituted radioactive nanodisc-embedded (A) MlaFEDB complex and (B) MlaFEB complex, following  
258 purification on a self-packed Superose 6 column. CB, Coomassie blue staining.

259 **SI References**

- 260 1. B. Ercan, W.-Y. Low, X. Liu, S.-S. Chng, Characterization of interactions and phospholipid transfer between  
261 substrate binding proteins of the OmpC-Mla system. *Biochemistry* 58, 114-119 (2019).
- 262 2. E.G. Bligh, W.J. Dyer, A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* 37,  
263 911–917 (1959).
- 264 3. S. Thong *et al.*, Defining key roles for auxiliary proteins in an ABC transporter that maintains bacterial outer  
265 membrane lipid asymmetry. *eLife* 5, e19042 (2016).
- 266 4. T. K. Ritchie *et al.*, Reconstitution of membrane proteins in phospholipid bilayer nanodiscs. *Methods*  
267 *enzymol.* 464, 211-231 (2009).
- 268 5. J.G. Nørby, Coupled assay of Na<sup>+</sup>,K<sup>+</sup>-ATPase activity. *Methods enzymol.* 156, 116–119 (1988).
- 269 6. K. Kiiianitsa, J. A. Solinger, W.-D. Heyer, NADH-coupled microplate photometric assay for kinetic studies of  
270 ATP-hydrolyzing enzymes with low and high specific activities. *Anal. Biochem.* 321, 266-271 (2003).
- 271 7. U.K. Laemmli, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature.*  
272 227, 680-685 (1970).
- 273 8. M. Swamy *et al.*, Blue native polyacrylamide gel electrophoresis (BN-PAGE) for the identification and  
274 analysis of multiprotein complexes. *Sci STKE* 345, pl4 (2006).
- 275 9. E. Molnár, Z. Kiss, L. Dux, F. Guba, Vanadate stimulated NADH oxidation in sarcoplasmic reticulum  
276 membrane. *Acta Biochim. Biophys. Hung.* 23, 63-74 (1988).